Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis

Abstract

Rituximab is effective at inducing and maintaining remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The wide interpatient variability in the duration of B-cell depletion and time to relapse as well as the significant relapse risk after treatment, costs, and adverse event rates necessitate improved patient stratification.

Keywords

• systemic-lupus-erythematosus
• anca-associated vasculitis
• activating factor gene
• rheumatoid-arthritis
• inference
• outcomes
• therapy
• disease